All News
Physician Burnout Remains, Less So in Rheumatology
The 2023 Medscape Survey on Physician burnout ranks rheumatology at #10; which is down from #2 when the survey was last done in 2021.
Read Article
ACR Urges CMS to Reconsider Copay Assistant Programs in CMS Proposed Rule
The Health and Human Services Notice of Benefit and Payment Parameters proposed rule for 2024 does not revise policies related to copay assistance and patient deductibles.
Read Article
Hope for Biologic Treatment of Hidradenitis Suppurativa
A meta-analysis of trials using biologics [adalimumab (ADA), ustekinumab (UST) and secukinumab (SEC)] in the the management of hidradenitis suppurativa (HS) suggests promising results, but more controlled, rigorous studies are needed.
Read Article
Herpes Zoster with JAK Inhibitors
JAK inhibitors are approved for several immune-mediated inflammatory diseases and carry a higher than usual risk of herpes zoster in certain conditions like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis.
Read Article
PNAS has a novel approach to #RA Tx; bioengineered probiotic(Lactobacillus reuteri) orally delivers a peptide Kv1.3 channel blocker to RxRA. Kv1.3 is expressed on CCR7− effector memory T cells. Blocking Kv1.3 improves RA & PSO in rat models. https://t.co/DyyXi2GUH2 https://t.co/8nDyFv9DWx
Links:
Dr. John Cush RheumNow ( View Tweet)
Deptof Veterans Affairs has awarded $1.2 million to Matlock Jeffries, MD of the Oklahoma Medical Research Foundation to study the connection between obesity, gut microbiome and cartilage changes leading to osteoarthritis of the knee. CONGRATS @matlockj https://t.co/M3807QD5K2 https://t.co/ypJNunbWWS
Links:
Dr. John Cush RheumNow ( View Tweet)
Swiss RA registry assessed outcomes after 1st JAKi. 400 RA pts starting/failing JAKi were switched to 2nd JAKi or TNFi or other MOA biologic. ~40% had prior bDMARDs. Retention was higher w/ 2nd JAK (918d)i vs other options. TNFi (335d) or OMA (918d). https://t.co/3A3KwVcTCN https://t.co/UFLPGfmzNv
Links:
Dr. John Cush RheumNow ( View Tweet)
Herpes Zoster with JAK Inhibitors
A recent review a higher HZ risk with JAKi therapy shows the HZ-risk in RA and UC to be higher than PsA when treated with usual doses of TOFA, especially those given higher TOFA doses or concomitant glucocorticoids.
https://t.co/BO7CgcuRKR https://t.co/gyMivn5YxL
Links:
Dr. John Cush RheumNow ( View Tweet)
Is JAKi therapy safe in RA-ILD pts? Italian retrospective study (2018-June 2022) w/ 43 RA pts & HRCT proven ILD (med age 69yrs) & Rx w/ JAKi. After 19 mos F/U, the FVC was stable in 79%, improved in 11%, & worse in 11%. DLCO & HRCT trend was similar. https://t.co/bAqa5wKIYE https://t.co/LnlcQtQnm8
Links:
Dr. John Cush RheumNow ( View Tweet)
The EMAs CHMP has recommended granting a marketing authorisation for Sotyktu (deucravacitinib) for the treatment of moderate to severe plaque psoriasis in adults. https://t.co/WztKcNDFl1 https://t.co/Cq3Cyr3YqX
Links:
Dr. John Cush RheumNow ( View Tweet)
Rretroperitoneal fibrosis Tx is fraut-steroids, tamoxifen, MMF, B cell therapy? OL trial in 8 RPF pts used steroids & mTOR inhibitor sirolimus (2mg/d x 3d; 1mg/d); 12 & 48wks - decr in fibrous tissue 50%, ESR 70%, IgG4 50% w/ normalized renal funct.
https://t.co/9BJchCctDi
Links:
Dr. John Cush RheumNow ( View Tweet)
RANKL-responsive epigenetic mechanism reprograms macrophages into bone-resorbing osteoclasts - study shows that NFATC1 associated superenhancer RNA, which is formed during osteoblast differentiation, can be used as a treatment target to reduce erosions https://t.co/gCITdJKPRP https://t.co/HENbYJcOId
Dr. John Cush RheumNow ( View Tweet)
Studies in 76 systemic sclerosis (SSc) pts (& animal models of SSc) show fibroblast A20 (enzyme) is downregulated and promotes fibrosis in SSc; but is repressed by DREAM, an A20 negative transcriptional regulator. https://t.co/30PuO4XRuq https://t.co/VJuAJHGbut
Dr. John Cush RheumNow ( View Tweet)
Join us at RheumNow Live this March!
Dr. Janet Pope ( @janetbirdnope) will be back to discuss decisive therapeutics in RA.
https://t.co/0IkJsGpH6s https://t.co/TwM6AAW97X
Links:
Dr. John Cush RheumNow ( View Tweet)
US population mortality rates compared dermatomyositis (DM) vs polymyositis (PM) in 1981 (12,249) & 2020 (23,608). Downward trend in DM/PM mortality (<7%); plus PM/DM was 2X more likely to be one of mult causes, instead of, sole cause of death. https://t.co/9KZKr8JxUE https://t.co/7acK0eHVku
Links:
Dr. John Cush RheumNow ( View Tweet)
Systematic review of MRI confirm degenerative meniscus tears compared arthroscopic meniscectomy (APM) vs non-surgical or sham Rx. Results: 10 trials, 605 patients showed at 24 mos F/U, no advantage in Function or QOL favoring APM - rec conservative Rx
https://t.co/4CwicQ9Jac https://t.co/3IrSRkNgqp
Links:
Dr. John Cush RheumNow ( View Tweet)
How do you treat latent TB? This and more on last week's RheumNow podcast.
https://t.co/4gUXFUDTFM https://t.co/TgT6ZyewZJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Can something as simple as a cup of coffee with milk have an anti-inflammatory effect in humans?
Apparently so, according to a new study. A combination of proteins and antioxidants doubles the anti-inflammatory properties.
https://t.co/As8lhxnifp https://t.co/eZKD8Y6oTx
Links:
Dr. John Cush RheumNow ( View Tweet)
Amgen launched its adalimumab biosimilar - Amjevita ( FDA approved in 2016), has 2 different discounts— 55% or 5% below Humira's (list $6,922/mo). Another report says Amjevita 40mg given q 2wk will cost $40,497 - $85,494 annually https://t.co/iGtJUa991N https://t.co/PTPTUskUaa
Links:
Dr. John Cush RheumNow ( View Tweet)
1st there was combined Rheum-Derm or Rheum-Pulm clinics. Medscape reports new Rheum-Cardiology clinics at Cleveland Clinic, NYU, Brigham, Stanford. Useful in research, managing Rheum pts a) at hi CV risk, B) having procedures/surgery, c) risk reduction https://t.co/9AqujArSMT https://t.co/3ZVORt9gK9
Links:
Dr. John Cush RheumNow ( View Tweet)